The Pan-Deacetylase Inhibitor Panobinostat Downregulates HIF-1α and VEGF and, Synergizes With Everolimus In Hodgkin Lymphoma Cell Lines

被引：4
|
作者：
Lemoine, Manuela [1 ]
Buglio, Daniela [1 ]
Jona, Adam [1 ]
Derenzini, Enrico [1 ]
Medeiros, L. Jeffrey [2 ]
Berry, Donald A. [3 ]
Younes, Anas [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Heniatopathol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Div Quantitat Sci, Houston, TX 77030 USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
10.1182/blood.V116.21.2851.2851
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1174 / 1175
页数：2
相关论文
共 39 条
  • [31] THE INFLUENCE OF THE HEAT SHOCK PROTEIN 90 (HSP90) INHIBITOR, NVP-AUY922, AND HYPOXIA ON THE EXPRESSION OF HIF-1α AND HIF-2α IN TWO HEAD AND NECK CANCER CELL LINES
    Bayer, C.
    Schilling, D.
    Multhoff, G.
    RADIOTHERAPY AND ONCOLOGY, 2012, 102 : S119 - S119
  • [32] Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
    Phillips, D. C.
    Xiao, Y.
    Lam, L. T.
    Litvinovich, E.
    Roberts-Rapp, L.
    Souers, A. J.
    Leverson, J. D.
    BLOOD CANCER JOURNAL, 2015, 5 : e368 - e368
  • [33] Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
    D C Phillips
    Y Xiao
    L T Lam
    E Litvinovich
    L Roberts-Rapp
    A J Souers
    J D Leverson
    Blood Cancer Journal, 2015, 5 : e368 - e368
  • [34] Co-treatment with NVP-BEZ235 and heat shock protein (hsp) 90 or pan-deacetylase (DAC) inhibitor is synergistically active against non-small cell lung cancer (N SOLO) cells with mutant RAS and LKB1
    Upadhyay, Sunil
    Fiskus, Warren C.
    Rao, Rekha
    Joshi, Atul
    Koul, Sanjay
    Balusu, Ramesh
    Mudunuru, Uma
    Buckley, Kathleen M.
    Quadt, Cornelia
    Atadja, Peter
    Garcia-Echeverria, Carlos
    Bhalla, Kapil N.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [35] Erratum: Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
    D C Phillips
    Y Xiao
    L T Lam
    E Litvinovich
    L Roberts-Rapp
    A J Souers
    J D Leverson
    Blood Cancer Journal, 2016, 6 : e403 - e403
  • [36] Combined Inhibition of Janus and Aurora Kinases by the Novel Small Molecule Inhibitor AZD1480 Induces Cell Death and Downregulates PD-L1 And PD-L2 Expression In Hodgkin Lymphoma
    Derenzini, Enrico
    Buglio, Daniela
    Katayama, Hiroshi
    Ji, Yuan
    Sen, Subrata
    Younes, Anas
    BLOOD, 2010, 116 (21) : 1173 - 1174
  • [37] Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199) (vol 5, e368, 2015)
    Phillips, D. C.
    Xiao, Y.
    Lam, L. T.
    Litvinovich, E.
    Roberts-Rapp, L.
    Souers, A. J.
    Leverson, J. D.
    BLOOD CANCER JOURNAL, 2016, 6 : e403 - e403
  • [38] Combination of Oral Nanatinostat, a Novel Histone Deacetylase Inhibitor, and the Oral Anti-Viral, Valganciclovir, Is Active in Relapsed/Refractory Epstein-Barr Virus-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results From a Phase 1b/2a Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 19 - 19
  • [39] Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV)-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results from a Phase 1b/2a Study
    Porcu, Pierluigi
    Haverkos, Brad M.
    Alpdogan, Onder
    Capra, Marcelo
    Feldman, Tatyana A.
    Brem, Elizabeth
    Vallurupalli, Anusha
    Brammer, Jonathan E.
    Schriefer, Ana
    Pereira, Juliana
    Tulpule, Anil
    Barta, Stefan K.
    Bryan, Locke J.
    Trauger, Richard
    Obrzut, Sebastian
    Gutheil, John
    Katkov, Afton
    McRae, Robert
    Royston, Ivor
    Faller, Douglas V.
    BLOOD, 2019, 134
1234